Is Titan Pharmaceuticals Finally Lining Up With the Big Boys?

Oct.14.10 | About: Titan Pharmaceuticals, (TTNP)

Titan Pharmaceuticals (NASDAQ:TTNP) has been on the rise over the past trading week, having hovered around the one dollar mark for some time. This, of course, seems decades away from the time that had TTNP trading for a couple of pennies before rocketing to the mid $2 range, although that event took place only last year, and made patient investors a killing. It looks like things could be heating up again, and TTNP may be ready to return some additional significant returns as Fanapt sales gain steam and the Probuphine trial winds down.

The recent rise of the VNDA share price may be offering us a clue as to what Fanapt is doing on the market, and an article published in the Journal of the American Medical Association (JAMA) regarding Probuphine Phase III data could be an indicator that Titan is finally lining up alongside the big players in the medical community.

The JAMA article refers to an already completed Phase III Probuphine trial and highlights the results, which showed that patients receiving Probuphine had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study.

Probuphine is a product of Titan's proprietary ProNeura subcutaneous implant drug delivery technology, and while Probuphine could be primed to roll right into the market of opioid addiction, the ProNeura technology holds an even greater deal of potential value for Titan, or for any company that may be looking to acquire TTNP.

The article is sure to bring renewed attention to Titan, and to the stock, and it could be a factor in why TTNP has run from ninety cents to a buck twenty five in such short time. The one dollar range wasn't exactly the steal that a buy of TTNP was at the one penny level, but it's looking like both prices could be distant memories if the current trend continues.

For now, let's watch for Vanda's quarterly report and see how sales of Fanapt are doing.

Disclosure: Long TTNP, no position VNDA.